Generics and biosimilars
Editorial
President's Message
President’s Message
Medical Writing. 2019;28(2):4–5
EMWA News
Feature Articles
Biosimilars: Change, challenge, and accomplishments
Medical Writing. 2019;28(2):60–65
Collecting metrics in medical writing – the benefits to you and your business
Medical Writing. 2019;28(2):85–87
Document management systems for medical writing
Medical Writing. 2019;28(2):88–90
ICMJE requirements for sharing individual participant data from interventional clinical trials
Medical Writing. 2019;28(2):66–73
Layperson materials in the sphere of biosimilars and generic medicines
Medical Writing. 2019;28(2):53–56
Medical writing for generics throughout the life cycle
Medical Writing. 2019;28(2):39–44
Medicinal products and medical devices in clinical trials conduct and disclosure
Medical Writing. 2019;28(2):74–80
Publication of clinical trial protocols and statistical analysis plans on ClinicalTrials.gov
Medical Writing. 2019;28(2):81–84
Regulatory pathways for development and submission activities
Medical Writing. 2019;28(2):8–19
Statistical principles in biosimilar development
Medical Writing. 2019;28(2):28–32